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Abstract
MicroRNA are emerging as powerful regulators of cell differentiation and tissue and organ development. Several
microRNA have been described to play a role in branching morphogenesis, a key step in early lung development.
However, considerably less attention has been paid to microRNA as regulators of the process of secondary
septation, which drives lung alveolarization during late lung development. Secondary septation is severely
perturbed in bronchopulmonary dysplasia (BPD), a common complication of preterm birth characterized by blunted
alveolarization. A number of studies to date have reported microRNA microarray screens in animal models of BPD;
however, only two studies have attempted to demonstrate causality. Although the expression of miR-150 was
altered in experimental BPD, a miR-150−/− knockout mouse did not exhibit appreciable protection in a BPD animal
model. Similarly, while the expression of miR-489 in the lung was reduced in clinical and experimental BPD,
antagomiR and over-expression approaches could not validate a role for miR-489 in the impaired alveolarization
associated with experimental BPD. This mini-review aims to highlight microRNA that have been revealed by
multiple microarray studies to be potential causal players in normal and pathological alveolarization. Additionally,
the challenges faced in attempting to demonstrate a causal role for microRNA in lung alveolarization are discussed.
These include the tremendous variability in the animal models employed, and the limitations and advantages
offered by the available tools, including antagomiRs and approaches for the validation of a specific
microRNA-mRNA interaction during lung alveolarization.
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Introduction
The development of the mammalian lung is broadly divided
into two phases: early and late lung development. Early
lung development occurs primarily in utero and involves
the separation of the early respiratory tract from the fore-
gut, and the branching of the conducting airways, along
with the associated vasculature [1]. Late lung development
is largely concerned with alveolarization: the formation of
the alveolar airspaces, which are the principal gas exchange
units of the lung. Alveolarization commences with the sac-
cular stage of lung development, where the distal airways
form saccular units at 24–38 weeks post-conception in
humans and embryonic day (E)18 to postnatal day (P)4 in
mice. This is followed by the alveolar stage of lung develop-
ment, where the saccular units are subdivided by secondary
septa, by the process of secondary septation [2]. This occurs
from approximately 32 weeks post-conception in humans,
where the bulk of postnatal alveolarization is undertaken
within the first 2 years of life; however, some degree of
alveolarization may persist into early adulthood [3]. In mice,
secondary septation initiates at P4 and is thought to be
largely complete by P28; however, some evidence suggests
that a slower rate of alveolarization continues for several
months [4]. Late lung development is a highly coordinated
sequence of events, and any disturbances to the process of
alveolarization result in severe perturbations to lung struc-
ture. This is exemplified by bronchopulmonary dysplasia
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(BPD), which is the most common complication of preterm
birth and which occurs in infants that receive oxygen sup-
plementation for acute respiratory failure [5]. In affected
infants, oxygen toxicity and baro- and volu-trauma associ-
ated with mechanical ventilation are believed to disrupt key
regulatory pathways that drive alveolarization. This results
in a pronounced impairment of late lung development,
which generates lungs that have fewer, larger alveoli, along
with thickened alveolar septa and a dysmorphic pulmonary
vasculature. The process of late lung development is very
poorly understood but involves the coordinated action of
growth and transcription factors, extracellular matrix
(ECM) remodelling, cell differentiation, and physical forces
[6–9]. Little is known about the regulation of—and integra-
tion of—these processes; however, amongst the emerging
candidate regulators of late lung development are
microRNA.
MicroRNA in early lung development
MicroRNA are a relatively new family of small, non-coding
RNA that play key roles in animal and plant development,
by regulating gene expression [10]. This is also true of the
lung, where several studies have already implicated and
validated roles for microRNA in early lung development.
Early studies revealed that the endoribonuclease Dicer,
which processes pre-microRNA to mature microRNA, was
required for lung epithelial morphogenesis [11], providing
indirect evidence of a role for microRNA in early lung de-
velopment. Subsequent microRNA microarray screens have
identified several microRNA candidates, such as miR-127,
as possible players in early lung development [12]. Similar
microarray studies have also highlighted sex-specific micro-
RNA expression profiles that are engaged in mice during
early lung development and which may explain the impact
of sex on aspects of normal and aberrant lung development
[13]. Confirmed roles for some microRNA in early lung
development have also been established using embryonic
lung explants and over-expression and gene deletion stud-
ies in mice in vivo. The miR-17-92 (Mirc1) cluster, which
includes multiple microRNA, is known to be highly
expressed during early lung development, but expression
declines as development proceeds. Over-expression of the
miR-17-92 cluster in alveolar epithelial cells (under control
of the Sftpc promoter) led to an abnormal lung and a lethal
phenotype and demonstrated that the miR-17-92 cluster
promoted a high proliferation rate and an undifferentiated
phenotype of lung epithelial progenitor cells [14]. Building
on this idea and using mouse lung explants, the miR-17
family was implicated in epithelial bud morphogenesis
through modulation of fibroblast growth factor (FGF)-10
signalling [15], which, along with reports (also using mouse
lung explants) that miR-140 modulated FGF-9 activity
during early lung development [16], highlighted multiple
microRNA as regulators of FGF function in the developing
lung. As with the miR-17-92 cluster, the miR-302-367
cluster (Mirc20) is also expressed at early stages of lung
development, and expression levels decline rapidly as devel-
opment proceeds. Using gain-of-function and loss-of-
function studies in the alveolar epithelium (under the con-
trol of the Sftpc promoter) in vivo, the miR-302-367 cluster
was demonstrated to control multiple aspects of lung endo-
derm progenitor cell behaviour that directed the formation
of a single-layered epithelium, which is ultimately required
for functional gas exchange capacity [17]. Staying with the
epithelium, several microRNA have also been implicated in
foetal alveolar type II cell differentiation, including the miR-
200 family [18, 19], miR-375 [20], and miR-124 [21]. The
mesenchyme has also received attention, where, using
embryonic lung explants, miR-142-3p was implicated in
the proliferation and differentiation of mesenchymal cells
during early lung development and in Wnt/β-catenin sig-
nalling [22]. A role for miR-142 in the modulation of Wnt/
β-catenin signalling in the lung was then confirmed in vivo,
using miR-142−/− mice [23]. In addition to Wnt/β-catenin
signalling, activity of the sonic hedgehog pathway was mod-
ulated by miR-326 in embryonic mouse lung explants,
which may influence epithelial-mesenchymal cross-talk
during early lung development [24]. To date, only one
study has addressed a role for microRNA in vascular devel-
opment during branching morphogenesis of the lung,
where miR-221 and miR-130a appear to have opposing
effects on tube formation and migration of mouse foetal
lung endothelial cells [25]. Thus, microRNA are emerging
as master regulators of epithelial, fibroblast, and endothelial
contributions to early lung development.
MicroRNA in late lung development
While a number of detailed descriptive and functional
studies have been undertaken during early lung develop-
ment (outlined above), considerably less work has been
undertaken addressing roles for microRNA in alveolari-
zation. Initial hints at candidate microRNA mediators of
alveolarization have been obtained using microRNA mi-
croarrays to identify temporal changes in the expression
of microRNA over the course of normal and aberrant
alveolarization, utilizing hyperoxia exposure [26–30], or
hyperoxia exposure after sterile (bacterial lipopolysac-
charide (LPS)-driven) maternal inflammation [31] in ani-
mal models of BPD (“experimental BPD”). MicroRNA
exhibiting changes in expression in the lung in response
to hyperoxia are listed in Fig. 1. MicroRNA that are
deregulated in experimental BPD and that have been
independently validated by real-time RT-PCR and/or
immunoblot are described in Fig. 2, together with vali-
dated microRNA targets. To date, three microRNA have
received particular attention in the context of BPD: miR-
206 [32], miR-150 [33], and miR-489 [26].
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The expression levels of miR-206 were reduced in both
experimental BPD in mice and in clinical (human) BPD
[32]. Fibronectin-1 (Fn1) was confirmed as a target of
miR-206 in lung epithelial cells, and consistent with this
idea, Fn1 expression was inversely correlated with miR-
206 levels. While these data highlight miR-206 as a can-
didate mediator of impaired alveolarization associated
with BPD, a causal role remains to be established.
A microRNA microarray also identified miR-150 as being
deregulated in experimental (hyperoxia-driven) BPD, where
lung expression of miR-150 was reduced [30]. Additionally,
glycoprotein nonmetastatic melanoma protein b (Gpnmb)
was identified and validated as a target of miR-150 [30].
These data suggested that decreased miR-150 levels would
lead to increased Gpnmb expression, which was indeed ob-
served in experimental BPD [33]. Consistent with this idea,
miR-150−/− mice exhibited increased Gpnmb expression.
When miR-150−/− mouse pups were exposed to hyperoxia,
a moderate protection of the lung structure was noted at
P9; however, no protection was evident at P13, where miR-
150−/− mice and wild-type mice exhibited a comparable
blunting of alveolarization in response to hyperoxia expos-
ure. Furthermore, the lung capillaries in miR-150−/− mouse
pups appeared dysmorphic. These data provide limited
support for a causal role for miR-150 in the aberrant lung
development associated with experimental BPD.
The expression of miR-489 in the lung was downregu-
lated in both experimental (mouse) and clinical (human)
BPD [26]. Both insulin-like growth factor (IGF)-1 and
tenascin C (Tnc) were identified as targets of miR-489,
and the expression of both IGF-1 and Tnc was increased
in the lung in experimental and clinical BPD, ostensibly
due to downregulation of miR-489 expression. These
data suggested that miR-489 may antagonize secondary
septation. However, blocking miR-489 function with a
locked nucleic acid antagomiR did not phenocopy the
effects of hyperoxia, and the use of antagomiR-489 in
vivo in the experimental BPD model paradoxically
Fig. 1 MicroRNA that exhibit altered pulmonary expression identified by microarray studies in experimental bronchopulmonary dysplasia.
Changes in microRNA expression are denoted by ↑ (for upregulation), ↓ (for downregulation), or↔ (no change). MicroRNA nomenclature (for example,
miR-34c versus miR-34c* and miR-34b-3p versus miR-34b-5p) have been adopted from the source articles and have not been standardized here. The
source articles are described by a number in square brackets
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improved lung structure. Also, contrary to expectations,
over-expression of miR-489 from a plasmid delivered to
developing mouse lungs worsened lung structure. As
such, although miR-489 levels were downregulated in
both clinical and experimental BPD, it appeared that
miR-489 was a negative regulator of secondary septation.
This study made the very important point that change in
the expression of microRNA under pathological condi-
tions (for example, BPD) suggests the possibility but
does not confirm a de facto role for the affected micro-
RNA as a pathogenic mediator. This study underscored
the importance of demonstrating a causal role in lung
alveolarization for any microRNA that exhibits expres-
sion changes in experimental BPD models.
Clearly, hyperoxia is not the only contributing causal
factor in the aberrant lung growth observed in clinical and
experimental BPD, where, for example, mechanical forces
(generating stretch) due to mechanical ventilation are also
an important factor that drives pathology [34, 35]. There is
a growing body of evidence that microRNA may also medi-
ate the effects of physical forces on lung development, in-
cluding normal and pathological alveolarization. For
example, in the context of asthma, it has been demon-
strated that miR-155 mediated the effects of mechanical
stretch on dynamic changes in the secretome of human
bronchial epithelial cells [36]. Indeed, an unbiased micro-
array screen has revealed that cyclic stretch can modulate
the expression levels of a broad spectrum of microRNA in
vitro, possibly contributing to stretch-associated alveolar
epithelial cell dysfunction [37]. However, a connection be-
tween microRNA and mechanical forces in lung alveolari-
zation has not yet been documented. Some data have also
been generated that addressed microRNA dynamics in de-
veloping lungs from rat pups that underwent intrauterine
growth restriction, caused by bilateral uterine artery
ligation. In these pups, perturbations to the expression
levels of miR-132 were noted, and miR-132 was proposed
to play a role in disturbing methyl CpG binding protein 2
expression and, hence, impact the epigenetic regulation of
alveolarization [38]. Thus, microRNA, in addition to medi-
ating the impact of hyperoxia on lung alveolarization, may
also mediate the effects of other injurious stimuli that im-
pact normal lung development.
It is important to consider that hyperoxia exposure or
other causal factors that drive aberrant lung alveolariza-
tion may concomitantly modulate microRNA expression
that, while without a direct functional impact on lung
development per se, may participate in pathogenic pro-
cesses related to comorbidities noted in BPD patients. By
way of example, microRNA that are produced in the al-
veolar epithelium play a critical role in the infection cycle
of respiratory syncytial virus (RSV) [39]. Similarly, micro-
RNA have an established role in the development of pul-
monary arterial hypertension, which often complicates
Fig. 2 MicroRNA that are proposed a play a role in aberrant lung alveolarization associated with experimental bronchopulmonary dysplasia. The
data reported here summarize trends the expression of selected microRNA (in bold) that have been noted in microarray studies and that were
independently validated (by real-time RT-PCR). Additionally, targets that have been validated by real-time RT-PCTR or immunoblot are also indicated in
parentheses. Changes in gene expression are denoted by ↑ (for upregulation), ↓ (for downregulation), or↔ (no change). MicroRNA nomenclature (for
example, miR-300 versus miR-300* and miR-139-3p versus miR-139-5p) have been adopted from the source articles and have not been standardized here.
The source articles are described by a number in square brackets
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BPD [40]. As such, injurious stimuli that drive perturba-
tions to microRNA dynamics in the lung and which cause
BPD may also facilitate the pathogenesis of microRNA-
dependent comorbidities. Conversely, alterations to
microRNA expression by co-morbidities may also directly
impact lung alveolarization, since, for example, RSV infec-
tion itself can alter microRNA expression in human lung
cells [41].
Studies on microRNA expression levels in peripheral
blood from very low birth weight preterm infants with
BPD have identified four microRNA that may serve as
biomarkers of BPD [42]. Of these four candidates, two
microRNA, namely miR-7 and miR-133b, exhibited in-
creased circulating levels in peripheral blood, while miR-
30a-3p and miR-152 levels were reduced. The potential
relevance of these four microRNA to the impaired alveo-
larization associated with BPD has not been established.
In view of these data, no causal role for any microRNA
in normal or aberrant alveolarization has yet been con-
firmed. Many additional candidates exist that have been
identified in the microarray studies described in Fig. 2,
most notable amongst these is the miR-29 family, which
has emerged in multiple studies. The outcome of these
causal studies is eagerly awaited.
Perspective: future work
Despite a large number of potential microRNA media-
tors of alveolarization, it is clear that a pressing priority
is to assign causality and demonstrate a functional role
for these microRNA in normal or aberrant lung alveolar-
ization. In the pursuit of this goal, the studies outlined
above have highlighted several potential pitfalls in how
investigators perform the necessary analyses. These pit-
falls are largely related to the models employed. For ex-
ample, Velten et al. [31] described increased expression
of miR-29b in the lung in response to hyperoxia (85 %
O2 for the first 14 days of life), while, in an alternative
model which entailed maternal administration of LPS to
mimic chorioamnionitis, prior to exposure of mouse
pups to hyperoxia (85 % O2 for the first 14 days of life),
an opposite trend (i.e. downregulation) of miR-29b ex-
pression in the lungs was noted. These data highlight
the critical importance of the selection of the BPD
model employed.
Along these lines, establishing a consensus about which
microRNA are deregulated in experimental BPD models is
sometimes problematic due to diverse nature of the experi-
mental BPD models employed. There is diversity in the ro-
dent species (rat [27, 30] versus mouse [26, 28, 29, 31–33]),
rodent strain (Kunmin [29, 32], C57BL/6J [26, 33], C3H/
HeN [31], ICR [28] mice, and Wistar [27] or Sprague-
Dawley [30] rats), and the duration and intensity of oxygen
exposure (60 to 100 %, applied either from within 12 h of
birth or from P3 or P4; with or without a post-hyperoxia
recovery period in normoxia, of varying durations), with or
without the pre-application of other injurious stimuli such
as LPS [31]. These concerns about the lack of
standardization of experimental BPD models have recently
been reviewed in detail by Silva et al. [8]. This variability in
experimental BPD studies must be kept in mind when
attempting to assign a causal role for selected microRNA in
alveolarization.
To date, only two studies have examined a causal role
for microRNA in experimental BPD, which addressed
miR-150 [33] and miR-489 [26]. One study utilized an
antagomiR approach, and another employed a global
knockout approach. While interesting, it must be kept in
mind that antagomiRs have considerable off-target effects
and may also neutralize related, relevant microRNA with
conserved “seed” sequences, although the antagomiR ap-
proach offers an easily applied and stable means of antag-
onizing microRNA function in a relatively specific fashion.
Both the antagomiR and global knockout approaches
effectively create a knockout animal. Given the increas-
ingly evident importance of cell-cell cross-talk and the
compartmentalization of physiological processes in the de-
veloping lung, the use of conditional, cell type-specific
driver lines is encouraged, which would permit the assign-
ment of a specific role to a specific microRNA in a specific
cell type in the developing lung. It is also important to ap-
preciate that microRNA (and antagomiRs) likely have a
multitude of messenger RNA (mRNA) targets in the lung.
Validation of a specific mRNA as a target of a specific
microRNA provides evidence of a possible causal relation-
ship but does not validate causality. To this end, the intro-
duction of Target Site Blocker (Exiqon) or Target
Protector (Qiagen)technology now permits the validation
of a specific microRNA-mRNA pair interaction in physio-
logical processes, although these approaches have not yet
been applied to the study of lung alveolarization.
Ultimately, the correlation of data generated in experi-
mental animal models must be validated in human stud-
ies, if the microRNA in question are to be proposed as a
pathogenic mediator of clinical BPD. Along these lines,
an exciting recent study by Rogers et al. [43] is the first
study in clinical material from BPD patients to demon-
strate that the expression levels of all members of the
miR-17-92 (Mirc1) cluster were downregulated in autop-
sied lung material from BPD patients and that the abun-
dance of miR-17 and miR-19b was reduced in the
plasma of infants that developed BPD. This is the first
study that points to potential causal role members of the
miR-17-92 (Mirc1) cluster of microRNA in clinical BPD.
These studies will no doubt be strengthened by the in-
creasingly broad spectrum of “-omics” methodologies
currently available to the research community [44].
Several recent studies have aimed to improve our ana-
lysis of the roles for microRNA in lung development,
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including a careful analysis of appropriate reference
genes for real-time RT-PCR studies [45]. Additionally,
efforts have been made to develop computational
methods for the integration of microRNA, microRNA
targets, and transcription factors into biologically rele-
vant pathways, circuits, and networks [46, 47]. These
and other technological advances will no doubt assist us
in better understanding the physiological roles of this
new and exciting family of non-coding RNA in lung
development.
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